Lee Yuchun
SEC CIK 1334365 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | Dir | 1,875 | — | $11.87M | 20 | 2022-04-04 | 2023-01-27 |
Most active insiders at VRTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| 2 | Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| 3 | Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| 4 | Bozic Carmen | EVP, CMO | — | $11.31M |
| 5 | WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| 6 | Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| 7 | McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| 8 | Biller Jonathan | EVP, CLO | — | $4.08M |
| 9 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| 10 | Bunnage Mark E. | EVP, CSO | — | $3.00M |
Lee Yuchun made no open-market trades at VRTX in the last 12 months.
Transactions 20
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-01-31 | 2023-01-27 | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | S - Sale+OE | $322.03 | -1,429 | 1,875 | -43% | -$460.2K |
| D | 2023-01-31 | 2023-01-27 | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | M - OptEx | $72.14 | +1,429 | 3,304 | +76% | +$103.1K |
| DM | 2023-01-27 | 2023-01-25+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | S - Sale+OE | $316.15 | -8,000 | 1,875 | -81% | -$2.53M |
| DM | 2023-01-27 | 2023-01-25+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | M - OptEx | $72.14 | +8,000 | 5,875 | New | +$577.1K |
| DM | 2023-01-25 | 2023-01-23+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | M - OptEx | $72.14 | +6,129 | 4,004 | New | +$442.1K |
| DM | 2023-01-25 | 2023-01-23+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | S - Sale+OE | $312.46 | -6,129 | 3,364 | -65% | -$1.92M |
| DM | 2023-01-19 | 2023-01-17+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | M - OptEx | $72.14 | +4,442 | 2,317 | New | +$320.4K |
| DM | 2023-01-19 | 2023-01-17+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | S - Sale+OE | $312.04 | -4,442 | 1,875 | -70% | -$1.39M |
| D | 2022-04-20 | 2022-04-18 | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | M - OptEx | $81.54 | +2,000 | 3,875 | +107% | +$163.1K |
| DM | 2022-04-20 | 2022-04-18 | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | S - Sale+OE | $284.23 | -2,000 | 3,493 | -36% | -$568.5K |
| DM | 2022-04-18 | 2022-04-14 | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | S - Sale+OE | $289.06 | -2,000 | 2,675 | -43% | -$578.1K |
| D | 2022-04-18 | 2022-04-14 | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | M - OptEx | $81.54 | +2,000 | 3,875 | +107% | +$163.1K |
| DM | 2022-04-14 | 2022-04-12+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | S - Sale+OE | $284.27 | -4,000 | 3,029 | -57% | -$1.14M |
| DM | 2022-04-14 | 2022-04-12+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | M - OptEx | $81.54 | +4,000 | 3,875 | New | +$326.2K |
| DM | 2022-04-12 | 2022-04-08+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | S - Sale+OE | $279.43 | -4,000 | 3,027 | -57% | -$1.12M |
| DM | 2022-04-12 | 2022-04-08+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | M - OptEx | $81.54 | +4,000 | 3,875 | New | +$326.2K |
| DM | 2022-04-08 | 2022-04-06+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | S - Sale+OE | $273.24 | -4,000 | 3,858 | -51% | -$1.09M |
| DM | 2022-04-08 | 2022-04-06+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | M - OptEx | $81.54 | +4,000 | 3,875 | New | +$326.2K |
| DM | 2022-04-06 | 2022-04-04+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | S - Sale+OE | $270.11 | -4,000 | 1,875 | -68% | -$1.08M |
| DM | 2022-04-06 | 2022-04-04+ | VRTX | Vertex Pharmaceuticals | Lee Yuchun | Dir | M - OptEx | $81.54 | +4,000 | 3,875 | New | +$326.2K |
Purchase Sale Sale after option exercise All abbreviations